Within3 provides a bespoke collaboration and communication service used to publish clinical studies, host advisory boards, and enable researcher and participant collaboration across the drug development process. The company says most of the top 20 pharmaceutical companies use its platform and it has users in more than 150 countries. Demand for its solution has surged during the COVID-19 pandemic as life-sciences organizations pursue virtual collaboration tools that meet compliance needs and scale enterprise-wide. Within3 reported explosive growth over the last 12 quarters and says it continues to break new records each month. The company raised over $100 million in new financing and will use the proceeds to continue product development and build additional capacity to support growth. Insight Partners and Silversmith Capital Partners participated in the financing. Within3 provides private, regulatory-compliant digital collaboration programs that enable pharmaceutical companies and other life sciences institutions to engage groups of health professionals around the world. The company’s platform is used by clients that include ten of the Top 20 pharmaceutical companies, mid-tier pharmaceutical companies, medical associations and hospitals, and large and boutique medical communications firms. Led by CEO Lance Hill, Within3 is headquartered in Cleveland, OH. The vendor focuses on expanding its customer base and supporting infrastructure. The company reported that its recent financing brings its aggregate funding to $20M.

Total raised

$100M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2020